Skip to main content

Table 1 Main demographics and clinical characteristics of patients with both ANCA-associated vasculitis and hepatitis E virus infection

From: Favourable outcome of acute hepatitis E infection in patients with ANCA-associated vasculitis

ID

Age (years)

sex

BMI (kg/m2)

Alcohol

Vasculitis type

ANCA

Vasculitic organ mani-festations

AAV disease status at HEV infection

BVAS at HEV infection

Time AAV diagnosis to HEV infection (months)

HEV infection symptoms

Hospitali-sation

Follow-up time after HEV infection (years)

#1

51

Male

21.6

None

EGPA

neg

ENT, PUL, PNS, CNS, CAR

Inactive

0

15

Epigastric pain

Weight loss

Headache

Fatigue

Light colored Stools

Dark colored urine

6 days

5

#2

36

Female

23.0

Rare

EGPA

neg

ENT, PUL, MUS, CUT

Inactive

0

81

Epigastric pain

Headache

7 days

2

#3

71

Male

25.4

1 beer per day

GPA

PR3

ENT, REN, CNS

Inactive

0

179

Dermal and scleral icterus

Jaundice

Light colored stools

Dark colored urine

Nausea

Vomiting

8 days

1.5

#4

58

Male

24.1

None

GPA

PR3

ENT, PNS, CUT

Inactive

0

2

None

4 days

12

#5

57

Male

31.5

None

GPA

PR3

PNS, MUS

Inactive

0

4

Fatigue

no

5

  1. ANCA, anti-neutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; CAR, cardiac; CNS, central nervous system; CUT, cutaneous; EGPA, eosinophilic granulomatosis with polyangiitis; ENT, ear, nose, and throat; GPA, granulomatosis with polyangiitis; HEV, hepatitis E virus; REN, renal; MUS, musculoskeletal; PNS, peripheral nervous system; PUL, pulmonary